公开(公告)号：US20160060273A1

公开(公告)日：2016-03-03

申请号：US14775265

申请日：2014-03-13

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo KASAI ,  Masaki OGINO ,  Ryo MIZOJIRI ,  Takeshi YAMASAKI ,  Hideki HIROSE ,  Nobuyuki TAKAKURA ,  Tohru YAMASHITA ,  Sachie MORIMOTO ,  Takashi NAKAHATA ,  Asato KINA

IPC: C07D498/10

CPC classification number: C07D498/10

Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

Abstract translation: 提供具有下式（1）表示的化合物或其盐，其具有SSTR5拮抗作用：其中每个符号具有与说明书中相同的定义。

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.